<DOC>
	<DOC>NCT00829114</DOC>
	<brief_summary>Non-randomized, comparative study (1:1 allocation) to study interactions between nevirapine-containing antiretroviral therapies and combined oral contraceptive pills.</brief_summary>
	<brief_title>Interactions Between Antiretrovirals (ARVs) and Combined Oral Contraceptives (COCs)</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives, Oral, Combined</mesh_term>
	<criteria>Willing to provide informed consent Willing to take COCs and follow all study requirements Has regular menstrual cycles every 2135 days (when not taking hormonal contraception) Last menstrual period (LMP) &lt;35 days before study entry Has body mass index of 1830 Negative urine pregnancy test as enrollment Documented HIV1 infection On nevirapinecontaining ART for at least three months (ART group only) CD4 cell count of greater than or equal to 350 (for nonARV group only) Currently sexually active and plans to stay sexually active for the next 6 months Medical contraindications to COC use Recent pregnancy (within 3 months) Has breastfed in last 3 months Last pregnancy was ectpoic Has been sterilized Has had any of the following conditions since last pregnancy, or since menarche if never pregnant: Pelvic Inflammatory disease Diagnosis of infertility Has had DMPA within 6 months or NET injectable within 3 months of study entry (or has had no menses since last injection regardless of its timing) has taken other hormonal therapies besides COCs (e.g., combined injectables, progestin implants or intrauterine systems, progestinonly contraceptive pills, medroxyprogesterone acetate, hormone replacement therapy) within 30 days of study entry Has an acute infection or other opportunistic diseases requiring therapy within 14 days before enrollment Has active drug or alcohol use that, in the opinion of the investigator, would interfere with adherence to study requirements Has taken any prohibited medication within 30 days before study entry Has chronic diarrhea, malabsorption or inability to maintain an adequate oral intake Has any condition (social or medical) which in the opinion of the investigator would make study participation unsafe or complicate data interpretation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>AE</keyword>
	<keyword>AIDS</keyword>
	<keyword>ALT</keyword>
	<keyword>ART</keyword>
	<keyword>AST</keyword>
	<keyword>DCF</keyword>
	<keyword>DMC</keyword>
	<keyword>FDA</keyword>
	<keyword>GCP</keyword>
	<keyword>HB sAg</keyword>
	<keyword>ICH</keyword>
	<keyword>IND</keyword>
	<keyword>IRB</keyword>
	<keyword>IU</keyword>
	<keyword>mg</keyword>
	<keyword>mm3</keyword>
	<keyword>PCR</keyword>
	<keyword>SAE</keyword>
	<keyword>ULN</keyword>
	<keyword>WB</keyword>
	<keyword>COC</keyword>
	<keyword>Combined Oral Contraceptives</keyword>
</DOC>